RT Journal Article
SR Electronic
T1 Efficacy and safety of convalescent plasma and intravenous immunoglobulin in critically ill COVID-19 patients. A controlled clinical trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.28.21254507
DO 10.1101/2021.03.28.21254507
A1 Gonzalez, Jose Lenin Beltran
A1 González Gámez, Mario
A1 Mendoza Enciso, Emmanuel Antonio
A1 Esparza Maldonado, Ramiro Josue
A1 Palacios, Daniel Hernández
A1 Campos, Samuel Dueñas
A1 Robles, Itzel Ovalle
A1 Macías Guzmán, Mariana Jocelyn
A1 García Díaz, Andrea Lucia
A1 Gutiérrez Peña, César Mauricio
A1 Reza-Escalera, Ana Lilian
A1 Tiscareño Gutierrez, Maria Teresa
A1 Galvan-Guerra, Elva
A1 Dorantes Morales, Maria del Rocio
A1 Medina, Lucila Martínez
A1 Monroy Colin, Victor Antonio
A1 Jose Manuel, Arreola Guerra
YR 2021
UL http://medrxiv.org/content/early/2021/03/31/2021.03.28.21254507.abstract
AB Background The proportion of critically ill COVID-19 patients has collapsed hospital care worldwide. The need for alternative therapies for this group of patients is imperative. This study aims to compare the safety and efficacy of convalescent plasma (CP) compared with human immunoglobulin (IVIg) in patients requiring the administration of high oxygen levels or mechanical ventilation.Methods This is a controlled, randomized, open clinical trial of patients with pneumonia secondary to SARS-CoV-2 infection, that fulfilled criteria for severe or critical disease. They were randomized in a 1:2 ratio; group 1 was administered IVIg at a dose of 0.3 grams per kilogram of ideal weight, in an 8-hour infusion every 24 hours, for 5 days. Group 2 was administered 200 ml of CP infused in 2 hours, for 2 days. The primary outcomes were duration of hospitalization and mortality at 28 days.Results One hundred and ninety (190) patients were randomized; 130 to the CP group, and 60 to the IVIg group. Their average age was 58 years (IQR 47 – 72), and most were male (n= 119, 62.6 %). On inclusion, 85.2 % of patients (n=162) were on invasive mechanical ventilation therapy. Overall mortality in all included patients was 53 % (n= 102), with a median follow-up of 14 days (IQI 8 – 26). Mortality at 28 days was 45.2 % (n=86). In the intention-to-treat analysis, there was no difference between groups neither in mortality on follow-up (53.8 vs. 53.3, p =1.0) nor at 28 days (46.2 vs 43 %, p=0.75, Log Rank p = 0.83). Per-protocol analysis between treatment groups revealed no difference in mortality throughout hospitalization (51.5 vs 51.4 %, p=1.0) nor after 28 days (42.1 vs 42.87 %, p=0.92 Log Rank p = 0.54). Only 23 patients in the CP group received plasma with detectable anti-SARS-CoV-2 antibodies.Conclusions In critically ill patients or on invasive mechanical ventilation for treatment of Covid-19, the use of CP is not superior to IVIg in terms of hospitalization duration or mortality. The use of CP is based on complex logistics and requires an assured level of antibodies if used therapeutically. IVIg does not appear to be useful in this group of patients.clinicaltrials.gov identifier: NCT04381858.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04381858Funding StatementNo external funding was receivedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the ethics committee of the Centenario Hospital Miguel Hidalgo, on April 15, 2020, with the identifier number 2020-R-25. It was also registered in the clinicaltrials.gov site with the identifier NCT04381858.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesContact the corresponding author directly by email